Figure 2.
A) ADCC results (mean ± SD) of SYD985, T-DM1 (ie, SYD995), Trastuzumab (ie, SYD 997) and ADC isotype control (ie, SYD 989) in two representative HER2 3+ expressing cell lines (ie, SARARK-6: ovary as the primary site and SARARK-9: uterus as the primary site). B) A representative 1+ HER2 expressing cell line (SARARK-7: ovary as the primary site). No significant differences in ADCC between SYD985, T-DM1, or Trastuzumab were detected in CS cell lines with different HER2 expression.